Pharmacom Labs puts letrozole into its Letros line, fifty tablets to the container at 2.5 mg each.
Letrozole belongs to the third-generation aromatase inhibitors: it binds the aromatase enzyme and halts conversion of androgen precursors into estradiol, which is what places it in anti-estrogen listings. The molecule is oral, non-steroidal and has no androgenic activity of its own. Pharmacom labels most of its range with a numeric suffix, and the 2.5 here is milligrams per tablet rather than any count or volume.
